EGF+61 A>G polymorphism does not predict response to first‐generation EGFR tyrosine kinase inhibitors in lung cancer patients

EGF+61 A>G polymorphism does not predict response to first‐generation EGFR tyrosine kinase inhibitors in lung cancer patients

Epidermal growth factor (EGF) and its receptor (EGFR) play a paramount role in lung carcinogenesis. The polymorphism in the EGF promoter region EGF+61A>G (rs4444903) has been associated with cancer susceptibility, but its role in lung cancer patients treated with tyrosine kinase inhibitors (TKIs)...

Full description

Bibliographic Details
Main Authors: Leticia F. Leal, Ana C. Laus, Rodrigo Cavagna, Flavia E. dePaula, Marco A. deOliveira, Dayana M. Ribeiro, Fernanda M. Hassan, José E. Miziara, Eduardo C. Albino daSilva, Vinicius D. daSilva, Pedro De Marchi, Rui M. Reis
Format: Article
Language:English
Published: Wiley 2020-10-01
Series:Thoracic Cancer
Subjects:
EGF+61 A>G polymorphism
EGFR
first‐generation TKI SNP
lung cancer
TKI
Online Access:https://doi.org/10.1111/1759-7714.13628

Internet

https://doi.org/10.1111/1759-7714.13628

Similar Items